Kedrion and Biotest Forge a Landmark Distribution Deal
Kedrion Biopharma Inc. and Biotest AG have officially announced their exclusive long-term distribution agreement for Yimmugo. This groundbreaking partnership emphasizes a commitment to enhancing patient care and access to vital immunoglobulin therapies in the U.S. market.
Contractual Agreement Highlights
The finalized contract stipulates that Biotest will supply Yimmugo to Kedrion, which will commit to purchasing minimum quantities over a seven-year term. This structured agreement ensures consistent availability of the medication for those who depend on it for management of Primary Immunodeficiency conditions.
Preparations for Launch
Preparations are already in motion for the anticipated market launch of Yimmugo, which is set for 2025. Both companies are focused on efficiently scaling production to meet increasing demand, following the approval of a Biologic License Application (BLA).
The Importance of Immunoglobulin Therapies
Immunoglobulin therapies like Yimmugo are vital in addressing the needs of approximately 500,000 individuals affected by Primary Immunodeficiencies (PID) in the U.S. These therapies significantly improve the quality of life for those affected, highlighting the importance of the recent agreement between Kedrion and Biotest.
Yimmugo Production Techniques
Yimmugo is manufactured using advanced production techniques at Biotest's newly FDA-certified facility in Germany. This facility employs state-of-the-art processes aimed at maximizing quality while ensuring resource efficiency. Such innovations are essential as the U.S. market for immunoglobulin therapies is projected to grow by around 9% annually over the next eight years.
Statements from Leadership
Bob Rossilli, Chief Commercial Officer at Kedrion, expressed enthusiasm about the venture, stating, "At Kedrion, we are committed to understanding the needs of patients and customers. We are thrilled to bring Yimmugo to the U.S. market where we see an incredible opportunity to make a positive impact on the lives of those who need it most." This sentiment underscores Kedrion's dedication to not just profit, but improving patient outcomes.
About Kedrion and Biotest
Kedrion Biopharma specializes in the collection and fractionation of blood plasma to produce essential therapies addressing a wide range of rare diseases, including Coagulation and Neurological Disorders, and more. With over 5,100 employees worldwide, Kedrion operates 68 plasma collection centers across the U.S. and is recognized as a global leader in the field.
Biotest AG, known for its high-quality plasma-derived therapies, is equally committed to advancing patient care. The partnership with Kedrion marks a significant step forward for Biotest, particularly in the U.S. market.
Contact Information
For more details, please reach out to Duccio Manetti, Chief Communication Officer. You can contact him via phone or explore Kedrion’s website for further inquiries.
Frequently Asked Questions
What is Yimmugo?
Yimmugo is a human immunoglobulin intravenous preparation used in treating primary humoral deficiency in patients aged 2 years or older.
When will Yimmugo be available in the U.S.?
The launch of Yimmugo in the U.S. is anticipated in 2025, with production already in progress.
How many people suffer from Primary Immunodeficiencies in the U.S.?
Approximately 500,000 people in the U.S. are affected by Primary Immunodeficiencies.
What are the potential risks associated with Yimmugo?
Potential risks include thrombosis and renal dysfunction; it is crucial to monitor patients closely and ensure proper hydration during administration.
Where is Yimmugo produced?
Yimmugo is produced at Biotest’s new FDA-certified facility located in Germany, utilizing state-of-the-art technology for high-quality production.
